Background and Aims: Placebo effect in health-related quality of life [HRQoL] 
Introduction

Inflammatory bowel diseases, comprising ulcerative colitis [UC] and
Crohn's disease [CD] , are believed to be triggered by an aberrant chronic immune response to the gut microbiome, catalysed by environmental and genetic factors, 1, 2 and are estimated to affect up to 0.5% of the general population in the Western World. 3 The clinical course of the IBD is characterised by periods of relapse and remission and only a minority of patients experience a chronic, continuous disease course. 4, 5 Medical approaches to bowel and non-bowel manifestations of IBD may be associated with side effects such as eye, bone, gastrointestinal, or liver dysfunction, as well as an overall impairment in the immune system with an increased risk of infections and autoimmune reactions. 6 In fact, both disease-related and therapy-related factors are known to induce a wide spectrum of physical, psychological, and social issues that impair IBD patients' quality of life. 4 Most of the IBD-focused clinical studies conducted in recent decades aimed to assess the efficacy of disease-modifying drugs on outcomes such as disease activity, need for hospitalisation and/or surgery, and side effects. 7 However, the Food and Drugs Administration [FDA] and the European Medicines Agency [EMA] have recently attributed a pivotal role to health-related quality of life [HRQoL] measures, emphasising that these should be included in drug development clinical trials. 8, 9 Indeed, assessing the HRQoL allows the performance of pharmacoeconomic analyses, which may be useful to guide future clinical decision making and health care policy. 10 In the particular case of IBD, outcomes reported by patients in clinical trials are mostly focused on health-related quality of life [HRQoL] , and are combined with data from the generic Short Form-36 questionnaire [SF-36] and a specific disease scale, such as the Inflammatory Bowel Disease Questionnaire [IBDQ] . 7 The placebo response is defined as the change that occurs in response to an inert or sham treatment used as a pharmacological control. 11 Even though the underlying mechanisms remain cryptic, the placebo response is thought to have a complex neurobiological basis, resulting from the interaction of expectation and conditioning. 12 Some authors consider that the influence of psychological health in gastrointestinal conditions stems from the brain-gut axis. 13 In what concerns IBD, two recent meta-analyses 12, 14 have pointed out that the placebo intervention is associated with improvements in clinical outcomes [response and remission] in both induction and maintenance trials. The impact of placebo interventions in subjective IBD outcomes is expected to be greater than that observed in objective endpoints. 13 Still, and to our best knowledge, no studies have been published on the effect of placebo in IBDs' HRQoL.
This paper aims to systematically review the published evidence regarding the placebo effect in the HRQoL of IBD patients, as well as to understand which factors underlie such an effect. The specific objectives were to analyse the placebo-treated patients concerning: i] mean IBDQ and SF-36 scores before and following placebo administration; and ii] the proportion of patients achieving IBDQ-defined response and remission, as well as the odd ratios for these two outcomes [ORs] calculated for placebo versus all active interventions.
Materials and Methods
Search strategy
This study was conducted following the recommendations of the Preferred Reporting Items for Systematic Reviews and MetaAnalyses [PRISMA] Guidelines 15 and the Cochrane Collaboration Guidelines for reporting meta-analyses. 16 Literature search included studies published until February 2018 using four electronic databases: PubMed . In order to ensure that all pertinent articles were included, the reference lists of the selected studies and previously published reviews were manually reviewed.
Eligibility criteria of randomised controlled trials
The following inclusion criteria were used: i] placebo-controlled randomised controlled trials [RCTs] assessing the effect of pharmacological interventions in HRQoL of adult patients with UC or CD; and ii] IBD diagnosis based on clinical, radiographic, endoscopic or histological criteria. The HRQoL scales considered in this study were the SF-36 and the IBDQ.
All studies that fulfilled at least one of the following conditions were excluded: i] systematic reviews, guidelines, comments, editorials, and letters; ii] studies involving patients with diseases other than CD and UC; iii] trials of probiotics, antibiotics, complementary therapies, or devices; and iv] articles written in languages other than English. No restriction in terms of publication dates was applied. Whenever full-text articles were unavailable, abstracts were included if considered critically relevant.
Study selection and data collection process
Two reviewers [MME and JA] carried out studies' screening and data extraction independently. Discrepancies were settled by consensus. Whenever the title and abstract clearly indicated that the study failed to meet the previously defined selection criteria, the report was immediately excluded from further analysis. The full text was analysed in all other studies.
The following information was collected from the selected studies: authors' name; publication year; cohorts' geographical origin; disease and severity; treatment regimen; duration of treatment and follow-up; number of patients enrolled in the intervention and placebo groups; concomitant therapies [medications allowed in the placebo arm]; dose and route of administration of the drugs being assessed; criteria used in the definition of clinical activity; scales used to assess HRQoL; HRQoL mean values at baseline and following placebo therapy according to IBDQ and SF-36; and the proportion of patients achieving remission and presenting the minimum clinically important difference according to the IBDQ.
The IBDQ scale was specifically designed to assess overall HRQoL in IBD patients and comprises data from four dimensions [bowel symptoms, systemic symptoms, social function, and emotional function]. The scores of this scale range from 32 to 224, with higher scores indicating better HRQoL. An increase of no less than 16 points was considered a clinically meaningful improvement [IBDQ response] and remission was defined as a total IBDQ score of ≥170 points. 17 The validity and reliability of this psychometrically validated instrument for measuring disease-specific HRQoL in patients with IBD have been previously established. 18 On the other hand, the SF-36 is a generic HRQoL comprising 36 items that are divided into two main domains (mental component summary [MCS] and physical component summary [PCS] ) and eight subscales [physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health]. 19 The use of the SF-36 scale for the IBD context was also previously validated. However, fewer consensuses exist regarding the clinically meaningful differences for this HRQoL assessment scale. Having taken into account the variations and other authors' recommendations, 20, 21 the range 3 to 5 points in SF-36 score was considered a clinical meaningful change.
Risk of bias assessment
Funnel plots were analysed to detect potential publication bias and/ or presence of systematic heterogeneity. The asymmetry of funnel plots comprising: i] all studies; ii] studies published before 2008; and iii] published since 2008 was assessed using the Eggers Test.
Afterwards, the quality assessment tool [QATSDD] was applied to each study by two authors in an independent fashion. This tool comprises 16 items that are scored from 0 to 3, reflecting intelligibility in the description of aims and setting, data quality, methodology, and self-assessment of each study. 22 Of the 16 QATSDD criteria, 14 were used in this systematic review; the two excluded items concern qualitative studies only. The overall quality score was obtained by dividing each study's total score by the maximum possible score [42 points].
Statistical analysis
Data were evaluated using random-effects meta-analysis methodology, which assumes that the estimations of the different studies are not identical but similar and follow some distribution. 23 The I 2 was used to evaluate the trials' heterogeneity: values above 50% were considered to indicate a substantial level of heterogeneity. 23 The stability of the estimations and the weight of each study in the heterogeneity analysis were assessed through sensitivity analysis, omitting one study at a time in a stepwise fashion. Review Manager version 5.3 was used to generate the forest and funnel plots and to calculate mean differences and corresponding 95% CIs, in order to compare the change of HRQoL scores before and after treatment with placebo. This software was also used to obtain the pooled proportion of IBDQ-defined response or remission and 95% confidence intervals [CIs] for the studies in which those rates were provided, as well as to calculate the odds ratios [Ors] 
Results
Bibliographic search and study selection
The selection strategy followed in this systematic review is summarised in Figure 1 . The database search yielded 328 records of which 55 were immediately excluded: 53 for being duplicates and two that were not written in English. The remaining 273 studies were evaluated by title and abstract screening and 210 were excluded: 96 whose outcomes were not within the scope of this systematic review, 79 that were not RCTs, 24 that did not involve IBD patients, nine that focused on non-pharmacological therapies, and two that were consensus papers. A total of 63 papers were then considered for full text analyses, from which 37 were excluded: 26 whose outcomes were not within the scope of this systematic review, eight that did not disclose results concerning the placebo arm, and three that used scales other than the IBDQ and SF-36 for the HRQoL assessment. Overall, 26 studies matched our inclusion criteria [ Table 1 ]. From these, 22 were used for IBDQ meandifference analysis, seven were used for SF-36 mean-difference analysis, seven were used for the assessment of the proportion of patients with clinically meaningful improvement in IBDQ and its corresponding OR, and six were used to calculate the proportion of patients in the placebo arm who achieved IBDQ remission and the corresponding OR.
Description of studies
The main characteristics of the 26 studies included in this systematic review are described in Table 1 19, 28, 33, 34, 37 analysed the maintenance stage, and four studies assessed both. 25, 40, 43, 45 The mean [± standard deviation] treatment duration was 8.70 ± 3.48 and 51.11 ± 9.43 weeks for induction and maintenance regimens, respectively.
Overall, 2842 patients receiving placebo were included in this systematic review: 54.5% of them were CD patients and 45.5% of them were UC patients. The number of patients in the placebo arm of each trial varied widely [ranging from 20 46 to 331 32 ]. The drug in the intervention arm was a biologic therapy in 19 RCTs: adalimumab in four 34, 40, 43, 45 ; natalizumab in three 25, 28, 38 ; infliximab in three 36, 37, 46 ; certolizumab 33, 35 and golimumab 39, 48 in two; vedolizumab, 19 fontolizumab, 41 antibody targeting α 4 β 7 integrin, 30 keratinocyte growth factor-2 31 and recombinant IL-10 42 in one trial each. Corticosteroids were used in two 29, 44 studies and tofacitinib, 17 rosiglitazone, 27 sargramostim, 26 and methotrexate 24 in the remaining four RCTs. In all but two 24, 29 RCTs, patients were allowed to take concomitant medications which were, in most cases, aminosalicylates, immunosuppressants, or corticosteroids.
The scales used for assessing patients' HRQoL were roughly the same among all studies: all of them provided data on the IBDQ, 10 19, 25, 26, 28, 33, 34, 36, 37, 42, 43 used the SF-36, four 26, 28, 33, 34 applied the visual analogue scale [VAS] , and three 19, 28, 33 used the European Quality of Life-5 Dimensions [EQ-5D]. Whereas the IBDQ scale was specifically designed to assess the overall HRQoL in IBD patients, the remaining three scales are generic HRQoL instruments that assess a wide range of dimensions and are applicable to several health states and conditions. 17 The quality assessment tool [QATSDD] scores are listed in Table 1 as percentages of the maximum possible score. These quality scores ranged from 54.8% 29 to 88.1%, 32 yielding an average [± standard deviation] quality score of 75.4 ± 9.6%. The highest scores were obtained for the parameters 'explicit theoretical framework', 'clear description of research setting', and 'description of procedure for data collection', whereas the lowest scores were found for the parameters 'statistical assessment of reliability and validity of measurement tools' and 'strengths and limitations critically discussed'. Overall, the methodological quality was moderate to high, suggesting a low to moderate risk of biased results.
Mean differences on IBDQ scores
Data concerning the mean IBDQ differences before and after placebo administration were pooled from 22 RCTs. In general, the distribution of trials on the funnel plot was asymmetrical, according to the results obtained with the Eggers test [p = 0.008], suggesting the existence of publication bias. On the other hand, when the studies from the past decade are separated from those remaining, it is observed that asymmetry exists among the studies published before 2008 [p = 0.017] but not among those published since then Records were identi ed through electronic database searching (n = 328) 55 studies were excluded: 53 were duplicates 2 not written in English 96 assessed outcomes not of interest 79 were not randomized controlled trials 24 did not enrol IBD patients 9 did not compare placebo to a pharmacological treatment 2 were consensus papers 26 assessed outcomes not of interest 8 did not provide data of placebo group 3 had different health-related quality of life scales 37 full-text articles were excluded: 22 used for IBDQ mean-difference analysis 7 used for SF-36 mean-difference analysis 7 used for assessing the proportion and OR of clinically meaningful improvement in IBDQ 6 used for assessing proportion and OR of patients achieving IBDQ remission 26 studies were included:
Records were screened by title and abstract (n = 273)
Full-text articles were assessed for eligibility (n = 63)
Identi cation
Screening Eligibility
Inclusion 210 studies were excluded: [p = 0.666; Supplementary Figure 1 To assess which factors were associated with this heterogeneity, univariate and multivariate analyses were carried out [ Table 2 ]. The following factors were found to be significant on the univariate analysis: i] number of patients in the placebo arm using 100 as the cutoff [p = 0 
Mean differences on SF-36 score
Even though data regarding SF-36 score were available in 10 trials, the values reported in three 19, 26, 43 of them were not complete enough to allow pooling mean differences before and after placebo administration. From the remaining seven studies, three assessed changes on SF-36 score of patients in the induction phase of the treatment [two with CD 25, 42 and one with UC]. 36 Considering the relatively low number of studies, these studies were stratified following the same Four studies 28, 33, 34, 37 presented the SF-36 scores before and following placebo administration in the setting of the maintenance regimen of CD therapy, and the pooled mean differences were 6.84 [95% CI: 2.62, 11 .06] and 6.65 [95% CI: 3.53, 9.78] for MCS and PCS, respectively [ Figure 3 ]. Significant heterogeneity was observed between the four studies.
IBDQ response and remission
Information regarding the number of patients in the placebo arm who experienced a minimum clinically important difference on IBDQ score [IBDQ response defined as a ≥16-point increase from baseline] was retrieved from five 17, 19, 28, 33, 36 
Discussion
The placebo arm of RCTs allows controlling for placebo responses and other incidental factors including detection biases, natural waxing and waning of symptoms, and regression to the mean. 49, 50 Even though placebos are designed to be inert and physiologically ineffective, recent evidence suggests that they may produce effects beyond those expected from diseases' natural history and clinical course, 12 precluding the detection of the intervention effects.
14 Recent studies 32, 51 have highlighted an increase of placebo response rates in IBD trials conducted over the years, and the impact of placebo on objective clinical outcomes of IBD patients was recently analysed in detail. 12, 14 However, even though greater changes are expected to occur in subjective outcomes, as far as the authors know there are no systematic data on the effect of placebo in health-related quality of life measures.
The results obtained for differences in IBDQ score following placebo administration were above the minimum clinically important difference [16 points ] in three settings: maintenance therapeutic regimen of CD patients, and induction and maintenance therapeutic phases of UC patients. There was a trend towards higher improvement in IBDQ mean scores following placebo administration during maintenance regimen. Also, the maintenance regimen was the only significant factor in the multivariate analysis. This finding is important for future study design and sample size calculation, as some IBD RCTs are integrated trials that include both induction and maintenance regimens and a second randomisation following induction therapy. 52 These usually have an 'enrichment design', in which patients responding to placebo during induction are excluded from the maintenance period, and placebo non-responders are re-randomised to receive intervention or placebo. 53 Consequently, integrated trials must include enough patients to ensure an adequate sample size for the maintenance regimen.
Mental component summary
In order to explore the higher HRQoL improvement during the maintenance phase, the design of the trials was investigated. Six 19, 25, 28, 33, 34, 37 of the seven studies just included patients with previous clinical response to pharmacological treatment during induction. The pooled mean difference on IBDQ for these trials differed from that reported on the single study that included patients that responded to either drug or placebo during the induction regimen. Even though the small number of studies hampers interpretation, this may suggest that the higher IBDQ values of placebo-treated patients during maintenance may be affected by a previous pharmacological response at induction which modulates both clinical course and patients' expectations.
The univariate analysis revealed that heterogeneity among trials could be related to the number of patients in placebo arm. Indeed, studies enrolling less than 100 placebo-treated patients systematically presented lower IBDQ mean difference values, suggesting that a small population size may not have the necessary power for detecting a minimally important effect. 54 In addition, changes in IBDQ mean scores were statistically superior in the placebo arms of the trials assessing the effect of biologic therapies. This may be due to the higher patient expectations regarding the efficacy of biologic therapy, which may contribute to the placebo response. 11, 55 Another factor that has to be underscored is that biologic trials were far more likely to allow concomitant medication [aminosalicylates, immunosuppressants, or steroids], which may contribute to the more robust placebo response in those trials. In fact, the univariate analysis suggested that those drugs could be factors influencing in a positive way the placebo effect in IBDQ scores, particularly corticosteroids and immunosuppressants. However, the reduced number of studies providing information on the percentage of placebo-treated patients receiving such medications hampers further interpretation.
It has been suggested that there is a trend towards higher placebo effect when the placebo is administered intravenously or subcutaneously rather than orally. 56 Significant differences for the variable 'route of administration' were not observed in our meta-analysis, which may be related to the fact that only two 17, 29 trials assessed orally administered drugs.
Limited information was available regarding changes on SF-36 score following placebo administration. A difference of three to five points in SF-36 score, regarded as a meaningful change, 20, 21 The pooled proportions of placebo-treated patients achieving IBDQ response and remission were 0.42 and 0.31, respectively. These values are higher than those available in the literature regarding clinical response and remission in UC 12 and CD 14,57 assessed using the Ulcerative Colitis Disease Activity Index, Mayo Activity Score, or Crohn's Disease Activity Index. Indeed, even though there is reasonable correlation between objective endpoint responses and HRQoL, some studies suggest that placebo effects are greater in patients' perception of their own improvement and self-rated measures, when compared with objective measures of disease activity. 58 The ORs of placebo-treated patients for achieving response and remission according to the IBDQ were lower than 1, meaning that the interventions analysed in all included trials are superior when compared with placebo in what comes to improve HRQoL. This study has some methodological limitations. First, there was significant heterogeneity among studies used for the mean differences analysis in what concerns induction and maintenance regimens of CD [both using IBDQ and SF-36 scales]. However, the exclusion of each study individually neither eliminated the heterogeneity nor changed considerably the pooled estimations. Yet, univariate analysis suggested that some factors might contribute to the high degree of heterogeneity, namely the number of patients in the placebo arm, the treatment regimen, and the type of drug used in the intervention. The variables used in the multivariate analysis were selected based on significance in the univariate regression. However, even though 'concomitant medication' was significant in the univariate analysis, it was not considered in the multivariate analysis since the number of studies reporting this variable was too small to include three study-level covariates in the model. The only significant factor influencing placebo-related IBDQ improvement in the multivariate analysis was the treatment regimen [maintenance versus induction]. Further investigation on heterogeneity would require access to individual participant data in order to compare subgroups within each trial and then combine these across trials. 59 Second, as the number of studies providing information on the proportion of patients who achieved IBDQ response and/or remission was small, the data of patients with CD and UC in induction and maintenance regimens were pooled together.
Third, due to the limited availability of data and large variations in trials' characteristics, some factors that could theoretically influence placebo effect on HRQoL could not be assessed, namely age distribution of the patients included in the placebo arm, baseline disease activity, disease duration preceding trial inclusion, duration of follow-up, and number of follow-up visits. Other factors that might influence the response and remission in the placebo arm were the smoking habits, psychological factors [including optimism, suggestibility, empathy, and neuroticism] as well as the psychiatric background of patients. 60 The information available regarding those characteristics was scarce, precluding further evaluation.
In brief, this systematic review and meta-analysis demonstrated that there is a clinically meaningful improvement in IBDQ mean scores following placebo administration and a significant improvement in SF-36 scores during both induction and maintenance regimens. Also, the pooled proportions of patients achieving response and remission according to IBDQ were 42% and 31%, respectively. Our results demonstrate that the placebo effect on IBD patients' HRQoL cannot be discarded during the design and analysis of a clinical trial. Still, and as expected, the ORs obtained for placebo arm were significantly below the reference when compared with the intervention arm [0.49 and 0.40 for IBDQ response and remission, respectively].
Understanding the placebo effect on measures of patient-perceived benefit, particularly on HRQoL, is of paramount importance, 52 considering that regulatory authorities [the FDA and EMA] are in the process of redefining clinical trials' endpoints, and inclusion of patient-reported outcomes as co-primary endpoints is very likely. 12 However, even though restoring quality of life is a therapeutic objective, the potential utility of patient-reported outcomes in clinical practice is yet to be determined.
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